2017 American Transplant Congress » Poster Session D: Liver: Immunosuppression and Rejection

Date: Tuesday, May 2, 2017

Time: 6:00pm-7:00pm

Location: Hall D1

Session Type: Poster Session

Meeting: 2017 American Transplant Congress

6:00pm-7:00pm: Acute Antibody-Mediated Rejection in Pediatric Liver Transplantation.

C. Eriksen,¹ M. Zimmerman,¹ J. Kim,¹ S. Lerret,² G. Telega,² B. Vitola,² J. Schiller,³ J. Hong.¹

6:00pm-7:00pm: An Investigation of Biopsy-Proven De Novo Autoimmune Hepatitis After Hepatitis C Clearance with Direct Acting Antivirals in Liver Transplant Patients.

R. Sigireddi, J. Moffett, M. Kueht, R. Ackah, A. Rana, C. O'Mahony, J. Goss, S. Dhingra, S. Khaderi.

6:00pm-7:00pm: Course of Inflammatory Bowel Disease Activity in Primary Sclerosing Cholangitis Patients Undergoing Liver Transplantation.

R. Parekh,¹ M. Segovia,² N. Kaur.¹

6:00pm-7:00pm: Delayed Calcineurin Inhibitor Introduction and Long Term Renal Outcomes in Liver Transplant Recipients Receiving Basiliximab Induction.

N. Lange,^1,2 D. Salerno,¹ C. Sammons.²

6:00pm-7:00pm: Effect of Hepatitis C (HCV) Treatment on Rejection Incidence and Severity in Post-Liver Transplant Patients.

C. Skillin, M. Mba, B. Madani, C. Frenette.

6:00pm-7:00pm: Evaluation of Renal Function After a Transition to Everolimus or Mycophenolate Mofetil in Liver Transplant Recipients.

C. Perez,¹ J. Fleming,¹ M. Sell,¹ B. O'brien,¹ A. Rogers,¹ I. Lee,¹ C. Mardis,¹ A. Mardis,¹ N. Patel,¹ H. Meadows,¹ N. Pilch,² K. Chavin,² D. Dubay,² R. Vinayak,² D. Taber.²

6:00pm-7:00pm: Everolimus Is Associated with Less Weight Gain Than Tacrolimus Two Years Following Liver Transplantation: Results of a Randomized Multicenter Study.

M. Charlton,¹ M. Rinella,² D. Patel,³ K. McCague,³ J. Heimbach,⁴ K. Watt.⁴

6:00pm-7:00pm: Graft-versus-Host Disease Following Deceased Donor Liver Transplant.

K. Putchakayala, S. Skorupski, S. Farhan, M. Chaffins, S. Ilias, H. Pahari, K. Collins, S. Nagai, M. Abouljoud.

6:00pm-7:00pm: Identification of a Stable Gene Signature of Transplant Tolerance to Liver Allograft by Meta-Analysis.

G. Gu, H. Hang, Q. Xia.

6:00pm-7:00pm: Impact of Donor Genotype on Recipient Tacrolimus Pharmacokinetics: The Liver Matters.

S. Tremblay,¹ T. Fukuda,² T. Mizuno,² E. Woodle,¹ B. Abu Jawdeh,¹ A. Govil,¹ U. Christians,³ J. Klawitter,³ A. Vinks,² R. Alloway.¹

6:00pm-7:00pm: Limited Impact of Pre-Existing Donor Specific HLA Antibodies on Long Term Survival After First Adult Liver Transplantation.

M. Koch,¹ M. Marget,² M. Sterneck,³ H. Thude,¹ B. Nashan.¹

6:00pm-7:00pm: Liver Transplant Recipients Undergoing Non-Transplant Surgeries and Everolimus Use as Primary Immunosuppressant- Busting the Myth of Wound Infection Due to mTOR Inhibitors.

S.-C. Hsu, A. Thorat, L.-B. Jeng, H.-R. Yang, P.-C. Li, C.-C. Yeh, T.-H. Chen, K.-S. Poon.

6:00pm-7:00pm: Liver Transplantation Outcomes Using Anti-Thymocyte Globulin Induction in Patients with Autoimmune Hepatitis.

S. LeCorchick, A. Sharma, I. Yakubu, C. Bhati, T. Reichman, L. Kang, M. Levy.

6:00pm-7:00pm: National Variation in Liver Transplant Immunosuppression in the U.S..

M. Nazzal,¹ R. Ouseph,¹ M. Schnitzler,¹ Z. Zhang,¹ D. Axelrod,² D. Segev,³ A. Naik,⁴ H. Randall,¹ D. Brennan,⁵ B. Kasiske,⁶ G. Hess,⁷ T. Alhamad,⁵ K. Lentine.¹

6:00pm-7:00pm: Plasma Cell Hepatitis in Primary Sclerosing Cholangitis Patients: 15-Year Experience at a Transplant Center.

J. Putra,¹ T. Schiano,² M. Fiel.³

6:00pm-7:00pm: Prospective DSA Monitoring and Significance of De Novo DSA in Adult Liver Transplantation.

S. Kubal,¹ R. Mangus,¹ J. Fridell,¹ B. Ekser,¹ R. Saxena,² N. Rush,² N. Higgins,⁴ M. Ghabril,³ M. Lacerda,³ A. Lobashevsky.⁴

6:00pm-7:00pm: Rapamycin Maintenance Therapy in Pediatric Liver Transplant Recipients Associated with Trend Toward Decreasing Th2 Cytokine Levels Compared to Tacrolimus Therapy.

R. Fischer,¹ A. Seng,² L. Gardner,² L. Steele,² L. Harvey,¹ H. Wasserkrug,¹ W. Andrews,¹ R. Hendrickson,¹ J. Daniel,¹ T. Yankee.²

6:00pm-7:00pm: Steroid-Free Immunosuppression After Liver Transplant for Autoimmune Disease Does Not Result in Increased Disease Recurrence.

A. Hooper,¹ C. Frenette.²

6:00pm-7:00pm: Subclinical Histologic Findings Are Observed in 25% of Stable Adult Liver Transplant Recipients (ALTRs) Screened for Immunosuppression Withdrawal (ISW): OPTIMAL (NCT02533180).

S. Chandran,¹ M. Abecassis,² J. Levitsky,² S. Feng,³ A. Humar,⁴ J. Emond,⁵ G. Klintmalm,⁶ A. Demetris,⁴ K. Much,⁷ L. Sun,¹ A. Priore,⁸ D. Ikle,⁷ N. Bridges,⁸ M. DesMarais,¹ B. Burrell,⁹ J. Markmann.¹⁰

6:00pm-7:00pm: This is Why We Can't Have Nice Things- Real World Experience with Everolimus in Livers.

C. Perez,¹ J. Fleming,¹ M. Sell,¹ B. O'Brien,¹ A. Rogers,¹ I. Lee,¹ C. Mardis,¹ A. Mardis,¹ N. Patel,¹ H. Meadows,¹ N. Pilch,² K. Chavin,² D. Dubay,² D. Taber.²

6:00pm-7:00pm: Treating Refractory Liver Allograft Rejection with Photopheresis.

I. Lopez Plaza,¹ A. Eisenbrey,¹ M. Raoufi,¹ A. Yoshida,² D. Moonka.²

6:00pm-7:00pm: Type of Surgical Procedures and Clinical Significance of Calcineurin Inhibitor Temporary Discontinuation Regarding LT Recipients Undergoing Major Elective Surgery.

C. Cho, J. Lee, K. Kim, S. Kim, J. Lee, K. Lee, J.-M. Kim, G.-S. Choi, C. Kwon, J.-W. Joh.

« View all sessions from the 2017 American Transplant Congress